Psoriasis Area and Severity Index ≤1 or ... A subset of patients have an aggressive form of the disease known as arthritis mutilans, which results in accelerated joint destruction and deformity.

and entheses of subjects with psoriasis. PsA may lead to progressive damage to peripheral joints and the spine that is occasionally rapid and severely destructive (arthritis mutilans). Erosive ...

MTX was approved by the Food and Drug Administration (FDA) in 1972 for severe psoriasis (which is often related to psoriatic arthritis), but it’s also been widely used “off-label” for PsA.

Psoriatic arthritis (PsA) develops in four stages: the preclinical stage, where those with psoriasis (PsO) are at higher risk but have no symptoms; the subclinical stage, where inflammation is ...

Bristol-Myers Squibb (BMY) stock in focus as psoriasis drug Sotyktu shows promising results in treating psoriatic arthritis ...